Head and Neck Cancer Chemoprevention Gets a Shot in the Arm
Authors:
- 20 January 2008
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (3) , 345-347
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Retraction: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. N Engl J Med 2004;350:1405-13New England Journal of Medicine, 2006
- Randomized Phase III Trial of Low-dose Isotretinoin for Prevention of Second Primary Tumors in Stage I and II Head and Neck Cancer PatientsJNCI: Journal of the National Cancer Institute, 2006
- Advances in the Biology of Lung Cancer ChemopreventionJournal of Clinical Oncology, 2005
- The convergence of cancer prevention and therapy in early-phase clinical drug developmentCancer Cell, 2004
- Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II TrialJournal of Clinical Oncology, 2001
- Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2001
- 13-cis-Retinoic Acid in the Treatment of Oral LeukoplakiaNew England Journal of Medicine, 1986
- Changes in Bronchial Epithelium in Relation to Cigarette Smoking, 1955–1960 vs. 1970–1977New England Journal of Medicine, 1979
- “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric originCancer, 1953
- TISSUE CHANGES FOLLOWING DEPRIVATION OF FAT-SOLUBLE A VITAMINJournal of Experimental Medicine, 1925